Table 2.
Baseline Clinical and Demographic Characteristics of All HPS and Non-HPS Waitlist Candidates
| Variable | HPS (n = 973) | Non-HPS (n = 59,619) | P value |
|---|---|---|---|
| Age at listing, median (IQR) | 53 (48–58) | 54 (48–60) | <.001 |
| Female sex, n (%) | 447 (45.9) | 21,881 (36.7) | <.001 |
| Race/ethnicity, n (%) | <.001 | ||
| White | 788 (81.0) | 43,693 (73.3) | |
| Black | 26 (2.7) | 4739 (8.0) | |
| Hispanic | 129 (13.3) | 8879 (14.9) | |
| Asian | 21 (2.2) | 1668 (2.8) | |
| Other | 9 (0.9) | 641 (1.1) | |
| Primary diagnosis, n (%) | <.001 | ||
| HCV | 447 (45.9) | 23,623 (39.6) | |
| NASH/cryptogenic | 198 (20.4) | 10,458 (17.5) | |
| EtOH | 175 (18.0) | 12,526 (21.0) | |
| Other | 64 (6.6) | 2554 (4.3) | |
| Autoimmune | 45 (4.6) | 3130 (5.3) | |
| Cholestatic | 31 (3.2) | 5682 (9.5) | |
| HBV | 13 (1.3) | 1645 (2.8) | |
| Listing laboratory MELD score, median (IQR) | 13 (11–16) | 16 (12–22) | <.001 |
| Listing laboratory MELD score category | <.001 | ||
| <15 | 610 (62.7) | 24,224 (40.6) | |
| 15–20 | 321 (33.0) | 17,526 (29.4) | |
| >20 | 42 (4.3) | 17,869 (30.0) | |
| History of ascites before listing, n (%) | 661 (67.9) | 48,618 (81.6) | <.001 |
| History of any hepatic decompensation event, n (%) | 700 (71.9) | 49,362 (82.8) | <.001 |
| Blood type, n (%) | .09 | ||
| O | 477 (49.0) | 27,526 (46.2) | |
| A | 360 (37.0) | 22,530 (37.8) | |
| B | 111 (11.4) | 7260 (12.2) | |
| AB | 25 (2.6) | 2293 (3.9) |
HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis.